DETERMINING CARRIER PROBABILITIES FOR BREAST CANCER-SUSCEPTIBILITY GENES BRCA1 AND BRCA2

Citation
G. Parmigiani et al., DETERMINING CARRIER PROBABILITIES FOR BREAST CANCER-SUSCEPTIBILITY GENES BRCA1 AND BRCA2, American journal of human genetics, 62(1), 1998, pp. 145-158
Citations number
29
Categorie Soggetti
Genetics & Heredity
ISSN journal
00029297
Volume
62
Issue
1
Year of publication
1998
Pages
145 - 158
Database
ISI
SICI code
0002-9297(1998)62:1<145:DCPFBC>2.0.ZU;2-Q
Abstract
Breast cancer-susceptibility genes BRCA1 and BRCA2 have recently been identified on the human genome. Women who carry a mutation of one of t hese genes have a greatly increased chance of developing breast and ov arian cancer, and they usually develop the disease at a much younger a ge, compared with normal individuals. Women can be tested to see wheth er they are carriers. A woman who undergoes genetic counseling before testing can be told the probabilities that she is a carrier, given her family history. In this paper we develop a model for evaluating the p robabilities that a woman is a carrier of a mutation of BRCA1 and BRCA 2, on the basis of her family history of breast and ovarian cancer in first- and second-degree relatives. Of special importance are the rela tionships of the family members with cancer, the ages at onset of the diseases, and the ages of family members who do not have the diseases. This information can be elicited during genetic counseling and prior to genetic testing. The carrier probabilities are obtained from Bayes' s rule, by use of family history as the evidence and by use of the mut ation prevalences as the prior distribution, In addressing an individu al's carrier probabilities, we incorporate uncertainty about some of t he key inputs of the model, such as the age-specific incidence of dise ases and the overall prevalence of mutations. There is some evidence t hat other, undiscovered genes may be important in explaining familial breast cancer. Users of the current version of the model should be awa re of this limitation. The methodology that we describe can be extende d to more than two genes, should data become available about other gen es.